PATENT CLAIM ANALYSIS

Application Number: 15952516
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["514", "006800"]

Abstract:
Methods of using FGF1 analogs, such as FGF1 mutant proteins having an N-terminal deletion, point mutation(s), or combinations thereof, to reduce blood glucose levels in subjects with steroid-induced diabetes, hypercortisolemia, or diabetes due to treatment with an antipsychotic agent, are provided. Such mutant FGF1 proteins can be part of a chimeric protein that includes a β-Klotho-binding protein, an FGFR1-binding protein, a β-Klotho-binding protein and a FGFR1-binding protein, a C-terminal region from FGF19 or FGF21.

Claim (Index 30):
The method of  claim 1 , wherein the mutated mature FGF1 protein comprises at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOS: 6, 7, 8, 9, 10, 11, 12, 13, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 113, 114, 115, 116, 117, 118, 119, 120, 173-175, 177-179, 181-183, 185-189, and 191-238.

Metadata:
- Claim Count in Document: 61.0
- Percentile: 91.0
- Lexical Diversity: 1.5614
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14520178', '14176992', '15283862', '15896469', '13641041']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8111539716707968
- 35 USC 102 Novelty (BERT): 0.6127216095901703
- Combined Prediction Score: 0.7913107354627341
- Mean Citation Score: 436.727788
- Max Citation Score: 675.9603
- Similarity Product: 460.1978555565476

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test